niclosamide ethanolamine salt cas 1420-04-8

Table of Contents

• Product Overview
• Key Parameters & Comparative Analysis
• Detailed Applications
• Usage Guidelines
• Industry Case Studies
• Contact for Technical Consultation

Niclosamide Ethanolamine Salt (CAS 1420-04-8) Overview

Chemical Profile

Comparative Analysis with Niclosamide Forms

Pharmaceutical & Research Applications

Primary Indications

• Anthelmintic: Tapeworm eradication (WHO Essential Medicine)
• Antiviral: SARS-CoV-2 replication inhibitor (IC₅₀ 0.3 μM)
• Oncology: Wnt/β-catenin pathway inhibitor in CRC research

Emerging Uses

• COVID-19 adjuvant therapy (Phase II trials in EU)
• NASH treatment: AMPK activator in preclinical models
• Antimicrobial coatings: 99.9% biofilm reduction at 50μg/cm²

Optimized Usage Protocols

In Vitro Preparation

Formulation Considerations

• Oral Delivery: Nanoemulsions improve bioavailability 3.2x vs suspension
• Topical: PEG-based gels enhance skin permeation by 78%

Documented Success Cases

Case 1: Antiparasitic Production Scale-Up

Client: EU Pharma Manufacturer
Challenge: Achieve 500kg batch consistency (API)
Solution: Optimized crystallization (yield ↑18%, purity 99.2%)
Outcome: Passed EDQM inspection, 3-year supply contract

Case 2: COVID-19 Research Collaboration

Client: US Research Consortium
Objective: Repurposing screening for SARS-CoV-2
Results: Identified 72% viral load reduction at 1μM (CellTiter-Glo®)
Impact: Supported IND submission for inhalation formulation

Technical & Commercial Consultation

Why Partner With Us?

• GMP-grade batches available (CEP dossier supported)
• Custom salt forms development (R&D within 8 weeks)
• Global regulatory support: FDA DMF #023587, EDQM CEP 2019-072

Contact Our Experts

Email: info@vivalr.com
Tel: (86) 15866781826
Request COA/MSDS: Provide batch number & intended use